Lifeboat Foundation

Blocking Immune System Pathway May Stop COVID-19 Infection, Prevent Severe Organ Damage

While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact. The key to one possibility — blocking a protein that enables the virus to turn the immune system against healthy cells — has been identified in a recent study by a team of Johns Hopkins Medicine researchers.

Based on their findings, the researchers believe that inhibiting the protein, known as factor D, also will curtail the potentially deadly inflammatory reactions that many patients have to the virus.

For that spooky season.

Who wants this to be their final ride?

In a world first, researchers from the University of Ottawa in collaboration with Israeli scientists have been able to create optical framed knots in the laboratory that could potentially be applied in modern technologies. Their work opens the door to new methods of distributing secret cryptographic keys—used to encrypt and decrypt data, ensure secure communication and protect private information. The group recently published their findings in Nature Communications.

“This is fundamentally important, in particular from a topology-focused perspective, since framed knots provide a platform for topological quantum computations,” explained senior author, Professor Ebrahim Karimi, Canada Research Chair in Structured Light at the University of Ottawa.

“In addition, we used these non-trivial optical structures as information carriers and developed a security protocol for classical communication where information is encoded within these framed knots.”

Southampton researchers have identified a blood profile that could help identify COVID-19 patients at greatest risk of deterioration and direct them towards trials of specific treatments that could modify their immune systems’ responses. A new study jointly led by Professor Tom Wilkinson and Dr Tristan Clark of the University of Southampton, has shown a blood test for five cytokines could help predict those at risk of life-threating overstimulation of immune defences by COVID-19, and potentially tailor their treatment to tackle this.

Southampton researchers have developed a blood test that could help identify COVID-19 patients at risk of a life-threatening overreaction of the body’s immune system.

In the race to launch smallsats into low earth orbit quickly and cost-effectively, operators and manufacturers have compromised on security and left themselves vulnerable to cyber attacks. Let’s not make Newspace a paradise for hackers.

Smallsat operators and manufacturers need to consider why their smallsats are so vulnerable to cyber attacks, the harm attacks can cause, cyber security weaknesses, why basic encryption is not enough and what can be done about it now. These are the issues that this article addresses.

NASA’s record-breaking OSIRIS-REx mission goes in for the space agency’s first-attempted asteroid surface sample on Tuesday. If successful, a sample from asteroid Bennu’s surface will arrive back at Earth in late September of 2023.

Varian has secured an investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin a clinical trial of FLASH therapy is an experimental treatment modality designed to deliver radiation therapy at ultra-high dose rates.

With ultra-high dose rates, FLASH therapy is said to be delivered in less than one second and more than 100 times faster compared to conventional radiation therapy.

The study, which is named as FAST-01(feasibility study of FLASH radiotherapy for the treatment of symptomatic bone metastases), will include the investigational use of Varian’s ProBeam particle accelerator that is modified to deliver an advanced non-invasive treatment option for cancer patients.

Continue reading “Varian gets FDA IDE approval to begin clinical trial of FLASH therapy” »

Our overarching vision: A world where data on all treatments that have been used against COVID19 are maintained in a central repository and analyzed so that physicians currently treating COVID19 patients know what treatments are most likely to help their patients and so that clinical trials can be appropriately prioritized.

Our team reviewed 2500+ papers & extracted data on over 9,000 COVID19 patients. We found 115 repurposed drugs that have been used to treat COVID19 patients and analyzed data on which ones seem most promising for clinical trials. This data is open source and can be used by physicians to treat patients and prioritize drugs for trials. The CDCN will keep this database updated as a resource for this global fight. Repurposed drugs give us the best chance to help COVID19 as quickly as possible! As disease hunters who have identified and repurposed drugs for Castleman disease, we’re applying our ChasingMyCure approach to COVID19.